Related Experiment Videos
[Evaluation of immunostimulating agents used in pulmonologic practice].
Vutreshni Bolesti
|January 1, 1989
Summary
Levamisole and Respivax effectively reduce relapses in chronic lung diseases by boosting the immune system. Other drugs like Gamma-A and dipyridamole show some immune or relapse-reducing effects.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Chronic lung diseases often involve immune system suppression.
- Recurrent infections necessitate effective immunomodulatory treatments.
Purpose of the Study:
- To evaluate the efficacy of immunostimulating drugs in patients with chronic lung diseases.
- To assess the impact of levamisole, Gamma-A, dipyridamole, and Respivax on immune components and disease recurrence.
Main Methods:
- Treatment of 161 patients with frequently recurring chronic nonspecific lung diseases.
- Inclusion of immunostimulating drugs: levamisole, Gamma-A, dipyridamole, and Respivax.
- Monitoring of immune system components and disease relapse rates.
Main Results:
- Levamisole and Respivax demonstrated significant antirelapse efficacy.
- Gamma-A exhibited a notable immunosubstituent action.
- Dipyridamole showed a moderate antirelapse effect.
Conclusions:
- Levamisole and Respivax are effective in managing chronic lung diseases by modulating immune responses.
- Immunostimulating agents offer potential therapeutic benefits for recurrent respiratory conditions.